1421373-99-0

Basic information

• Product Name: AZ 7550
• Synonyms: AZ7551 HCl;AZ7550 salt formate;Osimertinib Impurity 31;Osimertinib N desmethyl impurity 1;2-Propenamide, N-[4-methoxy-5-[[4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl]amino]-2-[methyl[2-(methylamino)ethyl]amino]phenyl]-
• CAS NO: 1421373-99-0
• Molecular Formula: C₂₇H₃₁N₇O₂
• Molecular Weight: 485.58074
• EINECS: -0
• Mol File: 1421373-99-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AZ 7550(CAS DataBase Reference)
• NIST Chemistry Reference: AZ 7550(1421373-99-0)
• EPA Substance Registry System: AZ 7550(1421373-99-0)

Safety Data

• Hazardous Substances Data: 1421373-99-0(Hazardous Substances Data)

Usage

Uses

AZ7550 is an impurity of the drug Osimertinib. Osimertinib is a selective EGFR inhibitor (epidermal growth factor receptor), used in the treatments of nonsmall-cell lung cancer (NSCLC).

Upstream product

• 1421372-94-2 N-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1-methyl-1H-indole-3-yl)-pyrimidine-2-amine 
• 1032452-86-0 2-chloro-4-(1'-methyl-1H-indol-3-yl)pyrimidine 
• 945016-63-7 3-(2-chloro-pyrimidin-4-yl)-1H-indole 
• 1421373-33-2 tert-butyl N-[2-[[5-methoxy-4-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-2-(prop-2-enoylamino)phenyl](methyl)amino]ethyl]-N-methylcarbamate 
• 1421373-34-3 tert-butyl (2-((2-amino-5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)(methyl)amino)ethyl)(methyl)carbamate 
• 1421373-35-4 tert-butyl (2-((5-methoxy-4-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-nitrophenyl)(methyl)amino)ethyl)(methyl)carbamate 
• 120-72-9 indole 
• 450-91-9 4-fluoro-2-methoxyaniline 
• 603-76-9 1-methylindole 

Relevant articles and documents

EGFR specific recognization fluorescent compound as well as preparation method and application thereof

The invention provides an EGFR specific recognization fluorescent compoundrepresented by a general formula I as well as preparation method and application thereof. The fluorescent compound can specifically recognize EGFR mutation and can be applied to specific detection of molecular typing of tumor cells, so that effective diagnosis and curative effect monitoring can be performed on tumor patients.

Compound for targeting decomposition of EGFR proteins and preparing method and application of compound

The invention discloses a compound for targeting decomposition of EGFR proteins with a structure shown in a formula or a pharmaceutically acceptable salt of the compound. In the formula, R representsC1-C6 alkyl groups, m is an integer of 1-7, and n is an integer of 1-6. The invention further discloses a preparing method of the compound, a drug composition comprising the compound or the pharmaceutically acceptable salt of the compound and a pharmaceutically acceptable carrier and a preparation prepared from the drug composition. The compound shows an excellent EGFR degradation effect and goodanti-tumor activity. Therefore, the invention further discloses application of the compound in preparing drugs for preventing or/and treating cancers. The compound has a huge application prospect in the field of medical treatment.

Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor

Epidermal growth factor receptor (EGFR) inhibitors have been used clinically in the treatment of non-small-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a number of years. Despite encouraging clinical efficacy with these agents, in many patients resistance develops leading to disease progression. In most cases, this resistance is in the form of the T790M mutation. In addition, EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea. We describe herein the evolution of an early, mutant selective lead to the clinical candidate AZD9291, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor. Following observations of significant tumor inhibition in preclinical models, the clinical candidate was administered clinically to patients with T790M positive EGFR-TKI resistant NSCLC and early efficacy has been observed, accompanied by an encouraging safety profile.